Board Meeting
The next board meeting for Finch Therapeutics Group Inc is on 01 Apr 2025 for the purpose of Finch Therapeutics Group Inc Annual Report for 2024
See details
Finch Therapeutics Group Inc Key Metrics
Select
All financials are in USD Million and price data in USD
VIEW MORE
Not Eligible
Expensive Valuation
Technically Neutral
Check Before You Buy
VIEW FULL CHECKLISTMedium rank
7Positive13Negative
35.0% Pass in checklist
Check P/E Buy Sell Zone
This stock has negative PE
Finch Therapeutics Group Inc Stock Price Analysis
Day Price Range | 14 (LTP) 1414.3 LowHigh |
Week Price Range | 14 (LTP) 13.614.3 LowHigh |
Month Price Range | 14 (LTP) 13.215.8 LowHigh |
52 Week Price Range | 14 (LTP) 0.815.8 LowHigh |
Finch Therapeutics Group Inc Live Price Chart
Switch to TradingView
Fetching data ...
Finch Therapeutics Group Inc Stock Analysis
Finch Therapeutics Group Inc stock analysis with key metrics, changes, and trends.
Finch Therapeutics Group Inc Metric | VALUE | CHANGE % | TREND | ANALYSIS | |
---|---|---|---|---|---|
Annual Revenue | $0.11 M | 57.71% | negative |
| |
Annual Net Profit | $74.75 M | 45.31% | positive |
| |
Price to Earning Ratio | -1.59 | - | negative |
| |
Stock Price | $14.00 | 384.43% | positive |
| |
Quarterly Net profit | $4.83 M | 30.45% | positive |
| |
Debt to Equity Ratio | 1.32 | - | negative |
| |
Return on Equity(ROE) | -126.06 % | -126.06% | negative |
| |
Mutual Fund Holding | 0.73 % | 0% | neutral |
| |
Institutional Holding | 2.85 % | 0% | neutral |
|
Loading data..
Finch Therapeutics Group Inc - Company Profile
What does Finch Therapeutics Group Inc do?
Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical date from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).
Finch Therapeutics Group Inc Management structure
All Gross Remunerations are in USD